Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 5 SUPPL., 1999, Pages

  Kurosawa, Motohiro ^a   Amano, Hiroo ^b   Kanbe, Naotomo ^b   Igarashi, Yasushi ^b   Nagata, Hiroshi ^c   Yamashita, Tetsuji ^d   Kurimoto, Fumihiko ^d   Miyachi, Yoshiki ^e  

^a HIROSAKI UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d LSI MEDIENCE CORPORATION   (Japan)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aggressive systemic mastocytosis; Chymase; Cyclosporin; Cytokine; Mast cell; Mediator; Methylprednisolone; Tryptase

Indexed keywords

CYCLOSPORIN; CYTOKINE; IMMUNOGLOBULIN E; INTERLEUKIN 6; METHYLPREDNISOLONE; STEM CELL FACTOR; TRYPTASE;

ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; HISTAMINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POINT MUTATION; PRIORITY JOURNAL; SKIN BIOPSY; SYSTEMIC MASTOCYTOSIS; TREATMENT OUTCOME;

BONE MARROW CELLS; CHYMASES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOLOGIC TESTS; HISTAMINE RELEASE; HUMANS; INFLAMMATION MEDIATORS; KARYOTYPING; MALE; MAST CELLS; MASTOCYTOSIS; METHYLPREDNISOLONE; MIDDLE AGED; SERINE ENDOPEPTIDASES; TRYPTASES;

EID: 0032988024     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70156-9     Document Type: Article

References (26)

1. Travis WD, Li C-Y, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease: analysis of 58 cases and literature review [published erratum appears in Medicine 1990;69:34]. Medicine 1988;67:345-68.
2. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2S-4S.
3. Metcalfe DD. The treatment of mastocytosis: an overview. J Invest Dermatol 1991;96:55S-9S.
4. Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992;326:619-23.
5. Longley J, Duffy TP, Kohn S. The mast cell and mast cell disease. J Am Acad Dermatol 1995;32:545-61.
6. Fiehn C, Prümmer O, Gallati H, Heilig B, Hunstein W. Treatment of systemic mastocytosis with interferon-γ: failure after appearance of anti-IFN-γ antibodies. Eur J Clin Invest 1995;25:615-8.
7. Igarashi Y, Kurosawa M, Ishikawa O, Miyachi Y, Saito H, Ebisawa M, et al. Characteristics of histamine release from cultured human mast cells. Clin Exp Allergy 1996;26:597-602.
8. 2 from cord blood mononuclear cells. J Immunol 1996;157:343-50.
9. TC types of human mast cells. J Histochem Cytochem 1989;37:1509-15.
10. McBride P, Bradley D, Kaliner M. Evaluation of a radioimmunoassay for histamine measurement in biologic fluids. J Allergy Clin Immunol 1988;82:638-46.
11. Stephan V, Zimmermann A, Kühr J, Urbanek R. Determination of N-methylhistamine in urine as an indicator of histamine release in immediate allergic reactions. J Allergy Clin Immunol 1990;86:862-8.
12. Enander I, Matsson P, Nystrand J, Andersson AS, Eklund E, Bradford TR, et al. A new radioimmunoassay for human mast cell tryptase using monoclonal antibodies. J Immunol Methods 1991;138:39-46.
13. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematological disorder. Proc Natl Acad Sci USA 1995;92:10560-4.
14. Obata T, Kobayashi T, Okada Y, Nakagawa N, Terawaki T, Aishita H. Effect of apeptide leukotriene antagonist, ONO-1078 on antigen-induced airway microvascular leakage in actively sensitized guinea pigs. Life Sci 1992;51:1577-83.
15. 4 in guinea-pigs. Clin Exp Allergy 1994;24:960-8.
16. Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon (letter). Acta Haematol (Basel) 1991;85:220.
17. Mutter RD, Tannenbaum M, Ultmann JE. Systemic mast cell disease. Ann Intern Med 1963;59:887-906.
18. 2 receptor antagonists. Dermatol 1992;184:149-52.
19. Olafsson JH, Roupe G, Enerbäck L. Dermal mast cells in mastocytosis: fixation, distribution and quantitation. Acta Derm Venereol (Stockh) 1986;66:16-22.
20. Naveh Y, Ludatscher B, Gellei B, Haim S, Friedman A. Ultrastructural features of mast cells in systemic mastocytosis. Acta Derm Venereol (Stockh) 1975;55:443-50.
21. Irani AA, Garriga MM, Metcalfe DD, Schwartz LB. Mast cells in cutaneous mastocytosis: accumulation of the MCTC type. Clin Exp Allergy 1990;20:53-8.
22. Algermissen B, Bauer F, Schadendorf D, Kropp JD, Czarnetzki BM. Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme-histochemical staining techniques. Exp Dermatol 1994;3:290-7.
23. Stellato C, de Paulis A, Ciccarelli A, Cirillo R, Patella V, Casolaro V, et al. Anti-inflammatory effects of cyclosporin A on human skin mast cells. J Invest Dermatol 1992;98:800-4.
24. 2 release from human lung mast cells by cyclosporin A. Int Arch Allergy Appl Immunol 1989;88:25-55.
25. 4 from human lung mast cells. Ricerca Clin Lab 1988;18:53-7.
26. Sperr WR, Agis H, Czerwenka K, Virgolini I, Bankl HC, Müller MR, et al. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. J Allergy Clin Immunol 1996;98:389-99.